Generics - Generics, Sandoz

Filter

Current filters:

GenericsSandoz

Popular Filters

1 to 25 of 34 results

Global oncology biosimilars market 2014-2018

28-11-2014

The global oncology biosimilars market is expected to expand at a compound annual growth rate (CAGR)…

BioconBiosimilarsCellTrionDr Reddy's LaboratoriesGenericsGlobalHospiraMarkets & MarketingMylanSandoz

New analysis of potential savings from Biosimilars in USA

New analysis of potential savings from Biosimilars in USA

04-11-2014

Introducing competing “biosimilar” versions of complex biologic drugs used to treat illnesses such…

Anti-Arthritics/RheumaticsBiosimilarsFinancialGenericsOncologyRegulationSandozUSA

United Thera scores over Sandoz in Remodulin patent case

United Thera scores over Sandoz in Remodulin patent case

31-08-2014

US biotech company United Therapeutics’ shares leapt 28.5% to $117.83 on Friday, after the company…

GenericsLegalNovartisPatentsRemodulinRespiratory and PulmonarySandozUnited TherapeuticsUSA

Tacrolimus Sandoz gets sole subsidy supply status in New Zealand

Tacrolimus Sandoz gets sole subsidy supply status in New Zealand

07-03-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has decided to award immunosuppressant drug…

Asia-PacificGenericsImmunologicalsMarkets & MarketingNew ZealandNovartisPricingSandozTacrolimus Sandoz

Sandoz to commercialize Taiwan Liposome’s antifungal

Sandoz to commercialize Taiwan Liposome’s antifungal

19-12-2013

Taipei-based biopharmaceutical company Taiwan Liposome Company has entered into a collaboration agreement…

Amphotericin BAntibiotics and Infectious diseasesAsia-PacificGenericsLicensingNovartisSandozTaiwan Liposome

Sandoz in deal to market authorized generic of Shire’s Adderall XR in USA

Sandoz in deal to market authorized generic of Shire’s Adderall XR in USA

03-12-2013

UK drugmaker Shire says that its subsidiary Shire US Inc has entered into an agreement to supply an authorized…

Adderall XRGenericsLicensingNeurologicalNorth AmericaNovartisSandozShire

Sandoz appeals US court decision on AzaSite patent

Sandoz appeals US court decision on AzaSite patent

06-11-2013

US ophthalmic care specialist InSite Vision says that Sandoz Inc, the US generics unit of Swiss drug…

AzaSiteGenericsInSite VisionLegalNorth AmericaNovartisOphthalmicsPatentsSandoz

Avanir agrees settlement with Sandoz over Nuedexta

14-08-2013

US drugmaker Avanir Pharmaceuticals (Nasdaq: AVNR) has entered into a settlement agreement with Swiss…

Avanir PharmaceuticalsGenericsLicensingNeurologicalNorth AmericaNuedextaPharmaceuticalSandoz

Court ruling favors Mylan in Copaxone patent dispute

17-07-2013

A US court has dismissed claims that US generic drugmaker Mylan (Nasdaq: MYL) infringed four patents…

CopaxoneGenericsMomenta PharmaceuticalsMylan LaboratoriesNatco PharmaNeurologicalNorth AmericaPatentsSandozTeva Pharmaceutical Industries

Sandoz initiates Ph III trial for biosimilar Enbrel

24-06-2013

Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has initiated a major Phase III clinical trial…

AmgenAnti-Arthritics/RheumaticsBiotechnologyDermatologicalsEnbrelGenericsNovartisResearchSandoz

Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent

19-06-2013

USA-based Actavis (NYSE: ACT), itself predominantly a generic drug marketer, and Japan's Kissei Pharmaceutical…

ActavisGenericsHetero GroupMen's HealthNorth AmericaNovartisPatentsPharmaceuticalRapaflo CapsulesSandoz

FDA warns Novartis on Austrian generic manufacturing plant cGMP failures

07-06-2013

The US Food and Drug Administration has written to Joseph Jimenez, chief executive of Swiss drug major…

Ebewe PharmaGenericsNovartisProductionRegulationSandoz

Global biosimilar drug revenues will reach $2,445 million in 2013, says Visiongain

08-05-2013

The world market for biosimilar drugs will be worth $2,445 million in 2013, growing by more than 20%…

BiotechnologyCellTrionGenericsGlobalHospiraMarkets & MarketingSandoz

EU Commission sends antitrust complaint to Johnson & Johnson and Novartis

01-02-2013

The European Commission has informed US health care giant Johnson & Johnson (NYSE: JNJ) and Swiss drug…

DuragesicEuropefentanylGenericsJanssen-CilagJohnson & JohnsonLegalMarkets & MarketingNeurologicalNovartisPatentsPharmaceuticalSandoz

US FTC puts divestment conditions on Watson's acquisition of Actavis

16-10-2012

The USA's Federal Trade Commission will require Watson Pharmaceuticals (NYSE: WPI) and fellow generic…

ActavisGenericsLegalMergers & AcquisitionsNorth AmericaNovartisPar PharmaceuticalsSandozWatson Pharmaceuticals

"Sandoz will be the leading biosimilars company in 2012," says Visiongain

04-10-2012

Sandoz, the generics unit of Swiss drug major Novartis (NVN: VX), will retain its position as the global…

BiotechnologyDr Reddy's LaboratoriesGenericsGlobalHospiraMarkets & MarketingNovartisSandoz

Novartis beats forecasts, despite generic and currency hits

19-07-2012

Second-quarter 2012 group net sales at Swiss drug major Novartis (NOVN: VX) came in at of $14.3 billion,…

AlconFinancialGenericsNovartisPharmaceuticalSandoz

Alabama Supreme Court ruling favors Sandoz in Medicaid pricing case

16-07-2012

The USA's Alabama Supreme Court came out in favor of Sandoz, the generics subsidiary of Swiss drug major…

GenericsLegalNorth AmericaNovartisPricingSandoz

1 to 25 of 34 results

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top